Top 50 Medical Device VC Funds & Investors in Switzerland (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
24 | Switzerland, Germany, Japan | Seed, Series A | Health Care, Medical Device, Biotechnology | $1.2M–$14M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
14 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Information Technology | $23k–$1.2M |
|
Verve Ventures
VC Fund
|
13 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$43M |
|
VI Partners
VC Fund
|
9 | Switzerland, Germany, United States | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.3M–$41M |
|
StartAngels Network
VC Fund
|
7 | Switzerland, Brazil | Seed, Series A, Series B | Medical, Health Care, Medical Device | $933k–$6.1M |
|
BioMedPartners
VC Fund
|
5 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$83M |
|
OCCIDENT
VC Fund
|
5 | Germany, Switzerland, Slovenia | Series A, Series B, Series C | Health Care, Biotechnology, Medical Device | $2.1M–$401M |
|
redalpine
VC Fund
|
5 | Germany, Switzerland, United Kingdom | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.6M–$59M |
|
Innosuisse
VC Fund
|
4 | Switzerland, United States, United Kingdom | Grant, Pre-Seed, Seed | Health Care, Biotechnology, Medical Device | $17k–$16M |
|
Translink Capital
VC Fund
|
4 | United States, China, South Korea | Series A, Series B, Series C | Software, Information Technology, Artificial Intelligence | $4M–$55M |
|
Zühlke Ventures AG
VC Fund
|
4 | Switzerland, Sweden, United States | Series A, Seed, Series B | Health Care, Medical Device, Medical | $1.2M–$11M |
|
4FO Ventures
VC Fund
|
4 | Switzerland | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.1M–$54M |
|
415 Capital
VC Fund
|
3 | Switzerland, United States, France | Series A, Series B, Series C | Medical Device, Health Care, Medical | $5.2M–$80M |
|
Neomed Management
VC Fund
|
3 | Switzerland, United States, Italy | Series B, Series C | Health Care, Biotechnology, Medical | $10M–$65M |
|
BlueOcean Ventures
VC Fund
|
3 | Switzerland, India, France | Seed, Series A | Health Care, Medical, Personal Health | $1M–$20M |
|
EIT Health
VC Fund
|
3 | United Kingdom, Spain, Ireland | Grant, Pre-Seed, Seed | Health Care, Medical Device, Medical | $22k–$1.6M |
|
Fongit Seed Invest
VC Fund
|
3 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
EVA Basel
VC Fund
|
3 | Switzerland | Seed, Series A | Biotechnology, Medical Device, Medical | $1.9M–$3.6M |
|
Alpana Ventures
VC Fund
|
3 | United States, Switzerland, Germany | Seed, Series A | Software, FinTech, Information Technology | $850k–$14M |
|
3wVentures
VC Fund
|
3 | Switzerland, Spain, Austria | Seed, Angel, Series A | Software, Health Care, Medical | $50k–$8M |
|
VitaTech S.A
VC Fund
|
3 | Switzerland, United States | Series A | Biotechnology, Medical Device, Therapeutics | |
|
Kickfund
VC Fund
|
3 | Switzerland, Germany | Seed, Pre-Seed, Convertible Note | Manufacturing, Medical, Health Care | $109k–$6M |
|
M Ventures
VC Fund
|
3 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
TiVentures
VC Fund
|
2 | Switzerland, Italy, United States | Seed, Series A | Software, Analytics, SaaS | $583k–$3.3M |
|
Initiative Capital Romandie
VC Fund
|
2 | Switzerland | Series A, Series B, Series E | Health Care, Biotechnology, Medical Device | $6.8M–$10M |
|
Evercurious VC
VC Fund
|
2 | Switzerland, Belgium, Germany | Seed, Pre-Seed | Health Care, Medical, Chemical | $1.2M–$7.7M |
|
SICTIC
VC Fund
|
2 | Switzerland, Germany, United Kingdom | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $233k–$2.9M |
|
Schroder Adveq
VC Fund
|
2 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5.6M–$100M |
|
Polytech Ventures
VC Fund
|
2 | Switzerland, United States, Spain | Seed, Series A | Financial Services, FinTech, Software | $1M–$9.7M |
|
Ecosystem Ventures
VC Fund
|
2 | United States, India, Switzerland | Seed, Series A | Mobile Apps, Mobile, Finance | $203k–$15M |
|
Swisscom Ventures
VC Fund
|
2 | Switzerland, United States, United Kingdom | Series B, Series A | Software, SaaS, Information Technology | $1.8M–$59M |
|
Molten Ventures
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B | Software, Information Technology, Financial Services | $3.2M–$60M |
|
New Enterprise Associates
VC Fund
|
2 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.3M–$103M |
|
Inkef
VC Fund
|
2 | The Netherlands, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2.2M–$88M |
|
Sofinnova Partners
VC Fund
|
2 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
Kinled Holding
VC Fund
|
2 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $648k–$40M |
|
M2care
VC Fund
|
2 | France, Switzerland | Seed | Medical, Hospital, Health Care | $1.1M–$2.9M |
|
Swiss Diabetes Venture Fund
VC Fund
|
1 | Norway, Sweden, Switzerland | Series A | Medical, Health Care, Medical Device | |
|
Steyn Group
VC Fund
|
1 | United Kingdom, Switzerland, South Africa | Seed, Series A, Series B | Advice, Hospital, CleanTech | |
|
Technology Fund
VC Fund
|
1 | Switzerland, Italy, Germany | Debt Financing, Grant, Seed | Software, Energy, Information Technology | |
|
HBM Partners
VC Fund
|
1 | United States, Germany, Switzerland | Series B, Series C | Biotechnology, Medical, Health Care | |
|
Astanor Ventures
VC Fund
|
1 | United States, France, United Kingdom | Series A, Seed, Series B | Agriculture, Biotechnology, Food and Beverage | $471k–$61M |
|
Wellington Partners
VC Fund
|
1 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3.1M–$55M |
|
European Union
VC Fund
|
1 | Germany, United Kingdom, United States | Grant, Seed | Software, Information Technology, Health Care | $16k–$31M |
|
NV Capital
VC Fund
|
1 | Switzerland | Series A | Wellness, Health Care, Medical Device | |
|
BB Biotech Ventures
VC Fund
|
1 | United States, Switzerland, Italy | Series C, Series A | Biotechnology, Health Care, Medical | |
|
Dental Innovation Alliance
VC Fund
|
1 | Belgium, Germany, Switzerland | Series A, Seed | Software, Health Care, SaaS | |
|
NEST pension fund
VC Fund
|
1 | Switzerland | Seed, Series A | Health Care, Biotechnology, Medical | |
|
Schroders
VC Fund
|
1 | United Kingdom, India, Canada | Series A, Series B, Series C | Medical, Biotechnology, Financial Services | |
|
European Commission
VC Fund
|
1 | Spain, France, Germany | Grant, Seed, Pre-Seed | Software, Biotechnology, Health Care | |
| Access all 275 VC funds in Switzerland Medical Device startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Seed, Series A
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 187
- Round size: Seed $1.2M–$6M; Series A $2.3M–$14M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- TestResults — TestResults uses the TrueTest technology and AI-based virtual user that makes it possible for the first time to test autonomously across software, system, and technology boundaries from a user perspective with the same approach. The company has simplified automated testing massively and reduced time radically. With it, the automation andmaintenance effort is reduced to a minimum that allows zero flakiness and the enlightening feeling of being in control of automation and test scenarios.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Information Technology
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 167
- Round size: Seed $117k–$1.2M; Grant $23k–$125k; Debt Financing $100k–$583k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- Phonemia — Phonemia is a digital health company that offers artificial intelligence and speech therapy services.
- MoleSense — Developing continuous molecular monitoring wearables to enable proactive healthcare.
- DiverSsiTy SA — DiverSsiTy SA develops personalized, patient-centric digital health technologies (DHTs) to improve the lives of patients suffering from neurodevelopmental disorders (NDDs), among which are those with autism spectrum disorder (ASD) and related comorbidities like attention-deficit/hyperactivity disorder (ADHD).
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 260
- Round size: Seed $1.4M–$10M; Series A $2.3M–$17M; Series B $4.2M–$43M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Biograil — Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery ofthe biologic efficiently into the gastrointestinal wall.
- iMusician — iMusician offers music distribution, promotion, mastering, and monetization for independent musicians & labels. Get on Spotify, Apple Music, Amazon, TikTok & many more.
Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 110
- Round size: Seed $1.3M–$6.5M; Series A $3.7M–$24M; Series B $3.3M–$41M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $117M in 2020
Portfolio highlights
- Altoida — Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.
- SMART VALOR — SMART VALOR is a secure investment platform offering easy buy and sell of cryptocurrencies like Bitcoin, Ethereum, Dash and more. Trade and store digital assets.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Brazil
Investor stats
- Total investments: 26
- Round size: Seed $933k–$3.7M; Series A $2.1M–$3.7M; Series B $1.7M–$6.1M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Calingo — Calingo is a digital insurance platform that offers personalised and optimised risk protection at the point of sale.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 87
- Round size: Series A $5.3M–$26M; Series B $4.9M–$83M; Series C $5.8M–$48M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- Vaximm — Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinicaltrials in 2011.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- Affimed — At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim toovercome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Series C
- Geography: Germany, Switzerland, Slovenia
Investor stats
- Total investments: 27
- Round size: Series A $2.1M–$12M; Series B $6.2M–$140M; Series C $7.8M–$401M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- ReCatalyst — REvolutionizing the way we make CATALYSTs for hydrogen technologies
- Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 181
- Round size: Seed $1.6M–$12M; Series A $3.2M–$31M; Series B $15M–$59M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $25M in 2013
Portfolio highlights
- Umiami — Umiami Technologies is a leader in plant-based meat. Our proprietary technology allows us to create clean-label and incredibly tasty foods.
- Albatross AI — Inspire Customers Boost Conversions Capture Missed Revenues
- Hypervision Surgical — Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging.
Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Grant, Pre-Seed, Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 222
- Round size: Seed $500k–$16M; Grant $51k–$2.9M; Pre-Seed $17k–$4.3M
- Lead/follow: 81% lead, 19% follow
Portfolio highlights
- Sparkli — Sparkli offers an AI-powered educational platform that turns children’s questions into interactive learning journeys called “expeditions.” The platform generates multimodal content blending visuals, audio narration, games, and quizzes to help learners explore topics and build skills like design thinking, financial literacy, sustainability, andemotional intelligence. It personalizes experiences using generative AI so that young learners engage with content aligned to their curiosity and interests. Sparkli also includes features to track progress and encourage regular engagement through challenges, rewards, and creative reflections. The platform supports both individual exploration and guided learning contexts for children.
- OrthoSens — OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech.
- Reverso Therapeutics — Reverso medicines is a biotechnology company that offers therapeutic medicines for anticoagulant therapy.
Translink Capital is a trailblazing Silicon Valley VC with unmatched institutional connections to Asia's economic powerhouses.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Series B, Series C
- Geography: United States, China, South Korea
Investor stats
- Total investments: 161
- Round size: Series A $4M–$27M; Series B $9.8M–$42M; Series C $10M–$55M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- nWay — nWay is the developer and publisher behind Power Rangers: Battle for the Grid, Power Rangers: Legacy Wars and Battlepalooza.
- Jobright — Discover your dream job with Jobright, your AI job search copilot. Find relevant opportunities tailored to your goals. Gain filtered matches, deep insights, and stay ahead with real-time company trends. Let Jobright find your perfect fit.
- Eclypsium — Eclypsium's platform enhances supply chain security by incorporating zero-trust in every device, fortifying hardware, firmware, and software.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Seed $1.2M–$3M; Series A $7M–$11M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Evismo — Diagnosing arrhythmias, sleep apnea, and stress directly in your practice. Digitally and efficiently. For general practitioners and specialists in Switzerland.
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
4FO Ventures
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland
Investor stats
- Total investments: 15
- Round size: Seed $2.1M–$3.6M; Series A $2.1M–$15M; Series B $6.4M–$54M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
415 CAPITAL is a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States and Israel.They primarily invest in innovative medical device technologies addressing cardiovascular disease: the worldwide leading cause of death and the single largest cost driver in the global healthcaresystem.We are investors AND entrepreneurs: As investors, They have funded 45 MedTech companies in the past 28 years. As entrepreneurs, They have founded, built, and exited several successful European MedTech distribution companies.
Show more...Investment focus
- Industry: Medical Device, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, United States, France
Investor stats
- Total investments: 14
- Round size: Series A $5.2M–$31M; Series B $35M–$49M; Series C $30M–$80M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
- CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C
- Geography: Switzerland, United States, Italy
Investor stats
- Total investments: 40
- Round size: Series B $20M–$65M; Series C $10M–$44M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Just another WordPress site
- Mikajaki — Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib.
- official.fm — At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label.They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collectinginsightful analytics. Improving your workflow is their top priority.Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: United Kingdom, Spain, Ireland
Investor stats
- Total investments: 95
- Round size: Seed $220k–$1.4M; Grant $22k–$1.6M; Pre-Seed $44k–$1.4M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- IDOVEN — IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
- eBreathie — eBreathie is a pioneering digital health startup offering an integrated asthma management solution. Our system comprises a smart inhaler (a medical device) that not only tracks WHEN patients take their medication but also HOW they do it, creating a detailed inhalation profile for each use. Paired with a user-friendly mobile app for patients and acomprehensive patient management platform for doctors, we provide real-time feedback on inhalation efficacy, ensuring patients and healthcare professionals have the insights needed for optimal asthma management. Leveraging IoT and AI, our goal is to reduce emergency visits, asthma attacks, and hospitalizations while ensuring effective inhalation techniques and optimal patient care.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 4
- Round size: Seed $1.9M–$3.6M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- AOT - Advanced Osteotomy Tools — AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy).
- POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more...Investment focus
- Industry: Software, FinTech, Information Technology
- Stage:Seed, Series A
- Geography: United States, Switzerland, Germany
Investor stats
- Total investments: 97
- Round size: Seed $850k–$4M; Series A $2.3M–$14M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
- Tinamu — Trusted inventory intelligence delivered in real-time
3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Angel, Series A
- Geography: Switzerland, Spain, Austria
Investor stats
- Total investments: 42
- Round size: Seed $50k–$3.8M; Angel $583k–$2.1M; Series A $1.2M–$8M
- Lead/follow: 2% lead, 98% follow
- Last fund: May invest from a new fund soon — raised $100M in 1999
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU Solutions — Discover how community-powered advice can turn your PDPs into trusted, high-converting content and get cited in AI search.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!VitaTech S.A
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Therapeutics
- Stage:Series A
- Geography: Switzerland, United States
Investor stats
- Total investments: 4
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aesyra — Aesyra makes innovative medical devices to help manage bruxism and improve your sleep.
- Gain Therapeutics — Discover Gain Therapeutics' next-gen allosteric small molecule therapies, combining physics-based methods and AI to address critical patient needs.
- Industrie Biomediche Insubri — IBI is an innovative hi-tech Swiss biomedical company focused on research, development and production of medical devices for tissue engineering and regenerative medicine: substitutes, grafts, 3D matrixes and 2D scaffolds.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, Germany
Investor stats
- Total investments: 37
- Round size: Seed $1.7M–$6M; Pre-Seed $335k–$4.4M; Convertible Note $109k–$121k
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Rhovica Neuroimaging — Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
- Cosaic — Cultivated - Creamy, dairy-free indulgence
- Ionic Wind Technologies — Ionic wind technologies, which use an internationally patented concept, alter the way airflow is generated. Instead of conventional rotating machinery, we move air with electric fields.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Biolinq — Introducing a revolutionary platform for metabolic health.
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the globalmarket. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.
Show more...Investment focus
- Industry: Software, Analytics, SaaS
- Stage:Seed, Series A
- Geography: Switzerland, Italy, United States
Investor stats
- Total investments: 23
- Round size: Seed $583k–$2.2M; Series A $1.9M–$3.3M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- InkVivo — InkVivo provides clinicians and healthcare providers with a product delivery system that optimizes treatments. Their manufacturing approach allows users to design implantable patches, tablets, and injectable biomaterials.
- Artificialy — Artificialy provides custom AI solutions, consulting, and training for enterprises in Switzerland and beyond. Artificial Intelligence actually delivered.
- Jaipur Robotics — Jaipur Robotics focuses on developing AI software for waste recycling ecosystem.
Initiative Capital Romandie is a private equity fund that focuses on technology companies based in Western Switzerland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Series E
- Geography: Switzerland
Investor stats
- Total investments: 6
- Round size: Series A $6.8M–$10M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- PicoDRILL — PicoDRILL generates technology leadership for its partner/customers through cutting-edge technology for drilling needs in the nanotechnology field. picoDrill is a private company located in Lausanne, Switzerland.
- Diagnoplex — Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity.
- Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Early stage deep-tech VC firm
Show more...Investment focus
- Industry: Health Care, Medical, Chemical
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Belgium, Germany
Investor stats
- Total investments: 7
- Round size: Seed $1.2M–$7.7M
- Lead/follow: 57% lead, 43% follow
Portfolio highlights
- ORamaVR — ORamaVR (www.oramavr.com) is a deep technology, spatial computing startup, innovating the field of med-ed-tech Virtual Reality (VR) training simulation authoring platforms. Our technologies are based on state-of-the-art research by world-renowned scientists team members. This research is turned into a novel, symbiotic VR authoring and simulationplatform by our top engineers, medical professionals and business developers. ORamaVR was founded in 2016 and received initial €575K pre-seed financing from the VC PJ TECH CATALYST FUND in Greece. The company has moved its HQ to Geneva, Switzerland upon strategic partners' demand. ORamaVR is adopted by the USC Keck School of Medicine, Los Angeles, NYU Langone Medical centre in New York, the University of Geneva and the Inselspital Hospital system in Switzerland, FORTH and the University of Athens in Greece and recently Western Governors University, Fayetteville State University and the University of Michigan in USA. Medacta International, a leading Swiss medical implant manufacturer expressed high interest to collaborate intensively with ORamaVR. ORamaVR has been awarded in 2020 an Epic Games Mega-Grant, in 2019 the Augmented World Expo (AWE) Auggie award for "Best Societal Impact” and the prestigious FARE award, from the American Association of Hip and Knee Surgeons (AAHKS) in 2018. ORamaVR has attracted more than €1.3M in R&D grants and awards up to date. In 2020 ORamaVR concluded a €370K bridge round led by HTC Vive, a leader in enterprise virtual reality.
- SolidWatts — We electrify industrial process heating by creating the new state-of-the-art in microwave and radio frequency power sources for industry.
- Co-reactive — Co-reactive is a ClimateTech startup that provides decarbonization of the construction industry at scale. Co-reactive works with suppliers of CO₂ and raw materials, manufacturers of cement and concrete, and certification bodies throughout the value chain to scale from pilot plants to large industrial units in the range of 100–300 kilotons. Feedback
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 128
- Round size: Seed $583k–$2.9M; Pre-Seed $233k–$2.1M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Qala — Qala delivers real-time data classification, discovery, and policy enforcement. Auto-classify sensitive data, map full lifecycles, and label at source.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Ionic Wind Technologies — Ionic wind technologies, which use an internationally patented concept, alter the way airflow is generated. Instead of conventional rotating machinery, we move air with electric fields.
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5.6M–$23M; Series B $11M–$83M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Seed, Series A
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 50
- Round size: Seed $1M–$5M; Series A $2.3M–$9.7M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Ecosystem Ventures, a Silicon Valley-based venture capital, offers investment and strategic consulting services to seed-stage companies.
Show more...Investment focus
- Industry: Mobile Apps, Mobile, Finance
- Stage:Seed, Series A
- Geography: United States, India, Switzerland
Investor stats
- Total investments: 27
- Round size: Seed $203k–$2M; Series A $700k–$15M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2009
Portfolio highlights
- GeoIQ.io — ML-ready location data and no-code AI for fintech
- SpeEdLabs — SpeEdLabs is to provide a top-notch, technology-based Learning and Practice platform to students at an affordable price, thus empowering every student to grow into their full potential.
- Mindler — Discover your perfect career, stream, college & course with India's leading career counsellors. Career counselling & guidance programs for school, college students & graduates.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 142
- Round size: Series A $1.8M–$23M; Series B $2.3M–$59M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Bring! Labs — Bring! Labs is an app for multi-device use that accompanies the user through all aspects of shopping for groceries and other everyday items. It offers grocery shopping for millions of people with shared shopping lists, integrated recipes, online shopping, local offers, and loyalty cards. Bring! Labs offers innovative mobile advertising platforms tocompanies in the retail and FMCG.
- Kandou AI — We enable faster and more energy efficient interconnects with a smaller physical footprint than competing technologies. Our chip connection technologies improves the speed to power consumption trade-off frontier.
- amnis — Check out your possibilities to transfer money abroad, collect international payments and exchange currencies all in one account. Make payments fast with amnis.
Molten Ventures is a leading British venture capital firm backing Europe’s highest-growth private technology companies. Our expert investment team stay ahead of the curve, identifying transformative trends and next-generation companies before they break through. We combine multiple pools of capital to invest at all stages of the businesslifecycle—from seed and early stage to growth and late stage—focusing on disruptive sectors like Spacetech, Fintech, and AI. Our strategy is simple: back bold ideas, scale them with capital and expertise, and unlock high-value exits—whether through strategic acquisitions, trade buy-outs, or IPOs. Since our 2016 IPO, we’ve delivered strong realised returns, reinvesting into the next wave of innovation—creating a virtuous cycle of growth and value.
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 221
- Round size: Series A $3.2M–$30M; Series B $7.9M–$60M
- Lead/follow: 52% lead, 48% follow
- Last fund: May invest from a new fund soon — raised $6.1M in 2011
Portfolio highlights
- Ledger — Secure your crypto assets such as Bitcoin, Ethereum, XRP, Monero, and more. Give yourself peace of mind by knowing that your cryptocurrencies are safe
- MAIA Technology — MAIA is a front-to-back asset management technology suite born out of an established asset management business with the pedigree of a decade of development and refinement.
- Freetrade — Invest in stocks and ETFs without commission when buying and selling shares. Instant online stock trading. Awarded best online trading app 3 years in a row.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1539
- Round size: Series A $5.3M–$60M; Series B $10M–$80M; Series C $13M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- Perplexity — Perplexity is a search engine platform that uses artificial intelligence to provide large language models and search engines. The company's platform enables the development of beneficial artificial general intelligence, as well as an open-source environment that is accessible to the public, allowing clients to develop skills and knowledge inartificial intelligence.
- Allay Therapeutics — SUPPORTING PATIENTS THROUGH EVERY PHASE OF RECUPERATION The first technology designed to deliver weeks of localized pain management
- Regulus Therapeutics — Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteinsbut instead regulate gene expression. It was founded in 2007 and is headquartered in Carlsbad, California.
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Germany
Investor stats
- Total investments: 85
- Round size: Seed $2.8M–$21M; Series A $3.2M–$42M; Series B $2.2M–$88M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $585M in 2016
Portfolio highlights
- Comet Therapeutics — DropCatch.com helps you secure expiring domain names.
- Salvia BioElectronics — Our mission is to give people with migraine a better life. As a pioneer in the field of medical devices, Salvia BioElectronics is passionately committed to empowering people with migraine to reclaim their lives.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 309
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
- l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 117
- Round size: Seed $648k–$11M; Series A $2M–$40M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
- PreComb — PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients.
M2care specializes in transformative innovation to create more efficient, equitable, and long-term models.
Show more...Investment focus
- Industry: Medical, Hospital, Health Care
- Stage:Seed
- Geography: France, Switzerland
Investor stats
- Total investments: 3
- Round size: Seed $1.1M–$2.9M
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- TheraSonic — TheraSonic aims to revolutionize the treatment of neurological diseases, particularly brain cancers.
- Rhovica Neuroimaging — Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Swiss Diabetes Venture Fund is europe’s first venture fund dedicated to diabetes technology.
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Series A
- Geography: Norway, Sweden, Switzerland
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
- GlucoSet — GlucoSet develops tools for accurate continuous glucose monitoring in Intensive Care Units, to reduce patient mortality and hospital costs.
- BOYDSense — BOYDSense specializes in developing non-invasive and affordable tools for measuring critical biomarkers via the exhaled breath. The company provides breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using it to diagnose and monitor chronicdiseases.It was founded in 2015 and headquartered in South San Francisco, California.
Steyn Group is a global single family office platform that specializes in private market investments. We provide infrastructure and zero time preference capital to support emerging investment managers and businesses.
Show more...Investment focus
- Industry: Advice, Hospital, CleanTech
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Switzerland, South Africa
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Bio-Logical — Bio-Logical offers technology to sequester carbon from agricultural waste and transform it into, climate resilience building fertiliser. This innovation is more than a product; it's a promise to regenerate land, dramatically boost crop yields, and tackle climate change head-on.
- Enko Education — [mk_page_section bg_image="https://enkoeducation.com/wp-content/uploads/2021/03/cnp-enko-399.jpg" blend_mode="darken" bg_position="center center" bg_repeat="no-repeat" bg_stretch="true" video_color_mask="#0a0a0a" video_opacity="0.3" min_height="0" pa...
- Carbon Capture Scotland — Carbon Capture Scotland seeks to get rid of carbon dioxide that has been organically stored in grains and barley.
Technology Fund offers loan guarantees to Swiss companies whose novel products contribute to a sustainable reduction in greenhouse gas emissions
Show more...Investment focus
- Industry: Software, Energy, Information Technology
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, Italy, Germany
Investor stats
- Total investments: 52
- Lead/follow: no public data
Portfolio highlights
- Distran — Distran ultrasonic cameras detect leaks of any type of gas in industrial facilities at a distance with live leak rate quantification. ATEX-certified.
- Bionomous — Bionomous - the world's first provider of AI-powered solutions for screening, sorting and dispensing of small biological entities. We are an innovative, agile
- AgroSustain — AgroSustain is a one-stop-shop solution for biological plant protection. It aims to reduce food waste and support organic food production by developing farm to fork solutions, like biological fungicides and coatings.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through allstages of development, focusing on adding value by leveraging its experience and HBM's world-wide network in the industry. Investments usually range between $5 million to $50 million.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series B, Series C
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 40
- Lead/follow: no public data
Portfolio highlights
- Dren Bio — Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
- Neuron23 — Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
- Mineralys Therapeutics — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Astanor Ventures is a venture capital firm focusing on entrepreneurs regenerating the food, blue ocean economy, and agriculture sector. The firm targeting technology-enabled companies across the agri-food value chain, leveraging disruptive technologies to bring about a future of food that is nourishing, regenerative, trusted, and ultra-fresh. Itrings together capital, deep sector knowledge, and a strong network of entrepreneurs, impact investors, technologists, scientists, farmers, chefs, policymakers, and food lovers to give rise to a future of food that is nourishing, regenerative, scalable, trusted, and delicious.
Show more...Investment focus
- Industry: Agriculture, Biotechnology, Food and Beverage
- Stage:Series A, Seed, Series B
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 74
- Round size: Seed $471k–$17M; Series A $8M–$36M; Series B $18M–$61M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Robovision — Deploy Industrial Vision Intelligence Infrastructure for packaging, food, semiconductor, healthcare and horticulture. Reduce waste, drift and total cost.
- MicroHarvest — MicroHarvest is an early-stage startup in Hamburg, Germany. The company is on a mission to produce better, healthier and tastier protein, produced sustainably using the power of microorganisms. Its proprietary and scalable technology allows producing nutritional biomass from fast-growing bacteria, with potential applications across the wholeprotein value chain. With that, MicroHarvest contributes to a world where everyone has access to nutritious food through a fair and resilient food system.
- Galley Solutions — Centralize recipe management, inventory controls, purchasing, & production in a single platform that is built for Culinary Operations.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 194
- Round size: Series A $3.1M–$33M; Series B $7.7M–$55M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $222M in 2019
Portfolio highlights
- nyra health — myReha is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. myReha was founded in 2020 and was headquartered in Vienna, Austria.
- UiPath — Reinvent your workplace with the leading robotic process automation platform and learn how UiPath can help your company become a fully automated enterprise.
- UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
Discover how the EU functions, its principles, priorities; find out about its history and member states; learn about its legal basis and your EU rights.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Grant, Seed
- Geography: Germany, United Kingdom, United States
Investor stats
- Total investments: 171
- Round size: Seed $16k–$5.5M; Grant $55k–$31M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Chessed.me — Chessed.me is a digital platform that improves children's concentration and cognitive abilities through individual chess lessons led by teachers.
- Adamo Foods — Adamo Food is a UK-based food tech company developing plant-based whole-cut meats using proprietary fermentation technology combined with mycelium.
- Dakar Mobilite — Dakar Mobilité is the Senegalese business that operates the Dakar BRT. The company is concerned with road safety, air pollution, and greenhouse gas emissions.
N & V Capital is a family-owned venture capital boutique focused on European investments. With generations of entrepreneurial experience, we seek scalable ventures driven by technology or scientific progress.
Show more...Investment focus
- Industry: Wellness, Health Care, Medical Device
- Stage:Series A
- Geography: Switzerland
Investor stats
- Total investments: 1
- Lead/follow: no public data
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series C, Series A
- Geography: United States, Switzerland, Italy
Investor stats
- Total investments: 29
- Lead/follow: no public data
Portfolio highlights
- Arvinas — Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Dental Innovation Alliance (DIA) is a venture capital company that invests in, advises on, and accelerates the growth of early-stage companies that are transforming dentistry through technology.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Series A, Seed
- Geography: Belgium, Germany, Switzerland
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Relu — Integrate Relu's automatic 3D segmentations seamlessly into your CBCT software.
- Odne — Curing with light
- Dentognostics GmbH — Dentognostics is a reasearch based firm that offers medicine and dentistry innovative and powerful systems for diagnostics, and therapy.
For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
- Comphya — CaverSTIM is a novel implantable device able to restore natural penile erection by neuromodulation.
- Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
As a global investment manager, we help institutions, intermediaries and individuals across the planet meet their goals, fulfil their ambitions, and prepare for the future.
Show more...Investment focus
- Industry: Medical, Biotechnology, Financial Services
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, India, Canada
Investor stats
- Total investments: 16
- Lead/follow: no public data
Portfolio highlights
- CeQur Simplicity — CeQur is revolutionizing mealtime insulin delivery to simplify the lives of people with diabetes and help them keep their blood glucose well controlled.
- Forteus — Forteus is an asset manager focused on blockchain technology and digital assets.
- Redcliffe Labs — Redcliffe LifetechRedcliffe Lifesciences specializes in reproductive health testing, rare diseases, and cancer genetic diagnostics. The company offers a wide range of advanced products and services for healthcare companies, research institutions, and other public and private partnerships, such as testing using molecular and gene-based diagnostics,therapeutic molecules and advanced therapies, next-generation sequencing, and all bioinformatics services.
The official website of the European Commission, providing access to information about its political priorities, policies and services
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Grant, Seed, Pre-Seed
- Geography: Spain, France, Germany
Investor stats
- Total investments: 187
- Lead/follow: no public data
Portfolio highlights
- Orfium — Find, use, track, and monetize music content across all channels with Orfium's industry-leading music rights management software.
- CyberRidge — CyberRidge is a deep-tech cybersecurity firm that develops photonic encryption to protect data privacy.
- Powerful Medical — Powerful Medical is a deep-tech company, tackling the most challenging problems of modern medicine using artificial intelligence and machine learning.
Medical Device VC funding in Switzerland at a glance
Stats across 379 deals from 275 investors.
Access all 275 VC funds in Switzerland Medical Device startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Device VC Funds in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 275 VC funds investing in Switzerland Medical Device startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!